SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment No. 1
Under the Securities Exchange Act of 1934
LYNX THERAPEUTICS, INC.
----------------------------
(Name of Issuer)
Common Stock par value $.001 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
551812 30 8
-----------------
(CUSIP Number)
William K. Hoskins, Esq. Harry R. Benz
General Counsel Hoechst Corporation
Hoechst Marion Roussel, Inc. Route 202-206
10236 Marion Park Drive P.O. Box 2500
Kansas City, Missouri 64137-1405 Somerville, NJ 08876-1258
(816) 966-4000 (517) 636-1000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 2, 1995
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(4)(i)(A) or (B), check the
following box. [ ]
Check the following box if a fee is being paid with this statement [ X ].
Page 1 of 6
Exhibit Index is at Page 4
<PAGE> 2
CUSIP No. 551812 30 8
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Marion Roussel, Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ X ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds WC
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 400,000*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 400,000*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 400,000*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 14.6%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Does not include an undetermined number of shares the reporting person is
obligated to purchase upon the happening of a future event - see Item 3.
<PAGE> 3
CUSIP No. 551812 30 8
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Corporation
I.R.S. Identification Number 22-1862783
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ X ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 400,000*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 400,000*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 400,000*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 14.6%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Does not include an undetermined number of shares the reporting person is
obligated to purchase upon the happening of a future event - see Item 3.
<PAGE> 4
This Amendment to Schedule 13D is filed solely to reflect the incorporation
by reference of certain documents.
The EXHIBIT INDEX of this Schedule 13D is amended to read as follows:
EXHIBIT INDEX
Exhibit No. Description Page No.
- ----------- ------------ ---------
99.A Series D Convertible Preferred Stock Purchase
Agreement dated as of October 2, 1995, by and
between HMRI and the Issuer (incorporated by
reference from Exhibit 10.29 to the Issuer's
Annual Report on Form 10-K for the year ended
December 31, 1995)
99.B Technology Development and Services Agreement
dated as of October 2, 1995, by and among
Hoechst AG, HMRI, and the Issuer (incorporated
by reference from Exhibit 10.28 to the Issuer's
Annual Report on Form 10-K for the year ended
December 31, 1995)
99.C Amended and Restated Investor Rights Agreement
dated as of November 1, 1995, by and among the
Issuer, HMRI, and the purchasers of the Issuer's
Series B Convertible Preferred Stock and Series
C Convertible Preferred Stock (incorporated by
reference from Exhibit 10.30 to the Issuer's
Annual Report on Form 10-K for the year ended
December 31, 1995)
99.D Agreement to File Jointly by and between HMRI 11
and HCorp dated March 21, 1996
99.E Information concerning directors and officers 12
of HMRI
99.F Information concerning directors and executive 13
officers of HCorp and Hoechst AG.
<PAGE> 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
HOECHST MARION ROUSSEL, INC.
Date: April 10, 1996 By: /s/ Charles D. Dalton
Charles D. Dalton
Vice President,
Assistant General Counsel,
and Assistant Secretary
<PAGE> 6
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
HOECHST CORPORATION
Date: April 10, 1996 By: /s/ David A. Jenkins
David A. Jenkins
Vice President, General
Counsel and Secretary
